Clinical Study Shows Zila's Ester-C(R) Superior to Vitamin C; Double-Blind Study Proves Ester-C Better Tolerated Than Regular V
May 04 2006 - 8:30AM
Business Wire
A clinical study of Ester-C manufactured by Zila, Inc.'s (Nasdaq:
ZILA), wholly-owned subsidiary, Zila Nutraceuticals, Inc., showed
that the Ester formulation of vitamin C caused significantly fewer
adverse epigastric effects (stomach upsets) and was much better
tolerated by the body compared to regular vitamin C. This was the
first double-blind, placebo-controlled study to evaluate whether
Ester-C causes fewer gastric upsets, the primary complaint of
vitamin C consumption, than regular vitamin C. The study was
published in a recent issue of Advances in Natural Therapy(R). "We
have known for years that Ester-C should be better tolerated than
regular vitamin C, also known as ascorbic acid. This being
confirmed in a double-blind, placebo-controlled human clinical
study gives vitamin consumers, a proven reason in addition to the
other benefits to take Ester-C," said Douglas D. Burkett, Ph.D.
Chairman, CEO and President of Zila. Ester-C is a pH neutral
advanced formulation of vitamin C, providing consumers, especially
those who are sensitive to acidic foods, with a form that is easier
for the body to tolerate. During the patented process of Ester-C
production, the ascorbic acid undergoes changes similar to those
that occur in the body. This results in enhanced levels of valuable
metabolites only found in Ester branded vitamin C. Ester-C is also
quickly absorbed and continues to work in the immune system for 24
hours. "As a practicing medical physician, I am always concerned
about `first doing no harm' when it comes to recommending either
pharmaceutical or nutraceutical products for my patients," says
Vern S. Cherewatenko, MD, MEd, a member of Zila's scientific
advisory board. "The recent study confirming that Ester-C has fewer
gastric complications and better tolerance keeps it as my first
choice when making recommendations to my patients. I also recommend
Ester-C to other clinicians considering which formulation to
recommend to their patients." About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is an innovator in preventative
healthcare technologies and products, focusing on enhanced body
defense and the detection of pre-disease states. Zila has three
business units: -- Zila Pharmaceuticals, marketer of products to
promote oral health and prevent oral disease, including ViziLite(R)
Plus oral examination kits and Peridex(R) prescription periodontal
rinse. -- Zila Biotechnology, a research, development and licensing
business specializing in pre-cancer/cancer detection through its
patented Zila(R) Tolonium Chloride and OraTest(R) technologies. --
Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and
Ester-E(R), branded, highly effective forms of Advanced Protection
vitamins C and E. For more information about Zila and Ester-C(R),
visit www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2005.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jul 2023 to Jul 2024